28.01
price up icon5.94%   1.57
after-market Dopo l'orario di chiusura: 28.30 0.29 +1.04%
loading
Precedente Chiudi:
$26.44
Aprire:
$28.095
Volume 24 ore:
1.34M
Relative Volume:
0.84
Capitalizzazione di mercato:
$2.65B
Reddito:
$522.75M
Utile/perdita netta:
$-558.99M
Rapporto P/E:
-4.3292
EPS:
-6.47
Flusso di cassa netto:
$-439.53M
1 W Prestazione:
+2.56%
1M Prestazione:
-23.95%
6M Prestazione:
-37.55%
1 anno Prestazione:
-38.00%
Intervallo 1D:
Value
$27.95
$28.52
Intervallo di 1 settimana:
Value
$25.81
$28.52
Portata 52W:
Value
$25.81
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
Nome
Ultragenyx Pharmaceutical Inc
Name
Telefono
415-483-8800
Name
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Name
Dipendente
1,294
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
RARE's Discussions on Twitter

Confronta RARE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
28.01 2.50B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-28 Iniziato William Blair Outperform
2024-06-06 Aggiornamento Goldman Neutral → Buy
2024-04-22 Iniziato RBC Capital Mkts Outperform
2023-12-08 Iniziato Wells Fargo Overweight
2023-06-14 Ripresa Credit Suisse Outperform
2023-06-06 Aggiornamento Evercore ISI In-line → Outperform
2023-04-26 Iniziato Cantor Fitzgerald Overweight
2023-01-18 Ripresa Canaccord Genuity Buy
2022-12-30 Ripresa H.C. Wainwright Buy
2022-11-03 Aggiornamento Robert W. Baird Neutral → Outperform
2022-10-13 Aggiornamento Guggenheim Neutral → Buy
2022-08-01 Downgrade Evercore ISI Outperform → In-line
2022-03-16 Aggiornamento Credit Suisse Neutral → Outperform
2022-02-11 Aggiornamento JP Morgan Neutral → Overweight
2021-09-30 Iniziato H.C. Wainwright Buy
2021-08-19 Iniziato UBS Sell
2021-07-15 Iniziato Guggenheim Neutral
2021-06-29 Aggiornamento BofA Securities Neutral → Buy
2021-06-04 Ripresa Robert W. Baird Neutral
2021-05-06 Aggiornamento Citigroup Neutral → Buy
2021-05-06 Aggiornamento Evercore ISI In-line → Outperform
2021-04-26 Ripresa Credit Suisse Neutral
2021-03-02 Ripresa Stifel Buy
2021-02-12 Downgrade JP Morgan Overweight → Neutral
2020-12-07 Downgrade Wedbush Outperform → Neutral
2020-11-24 Ripresa Evercore ISI In-line
2020-11-12 Downgrade BofA Securities Buy → Neutral
2019-08-02 Ripresa Wedbush Outperform
2019-03-27 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2019-02-22 Ripresa Raymond James Outperform
2019-01-02 Downgrade Raymond James Outperform → Mkt Perform
2018-11-08 Aggiornamento Citigroup Sell → Neutral
2018-09-10 Iniziato Morgan Stanley Equal-Weight
2018-06-21 Downgrade Credit Suisse Outperform → Neutral
2018-05-11 Aggiornamento Barclays Equal Weight → Overweight
2018-05-10 Iniziato Goldman Neutral
2018-04-18 Aggiornamento SunTrust Hold → Buy
2018-03-22 Ripresa Piper Jaffray Overweight
2018-02-21 Reiterato Stifel Buy
2018-01-22 Aggiornamento Evercore ISI In-line → Outperform
2018-01-18 Iniziato Credit Suisse Outperform
2017-12-05 Reiterato Barclays Equal Weight
2017-12-04 Aggiornamento Jefferies Hold → Buy
2017-09-14 Aggiornamento Wedbush Neutral → Outperform
Mostra tutto

Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie

pulisher
Jul 23, 2025

Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Ultragenyx Pharmaceutical Inc. stock priceRapid portfolio appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.

Jul 23, 2025
pulisher
Jul 22, 2025

RARE ACTIVE INVESTIGATION: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Ultragenyx Pharmaceutical Inc. stockUnmatched profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ultragenyx Pharmaceutical (RARE) Gets a Complete Response Letter for UX111 - Insider Monkey

Jul 22, 2025
pulisher
Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

Is Ultragenyx Pharmaceutical Inc. a good long term investmentConsistently high returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

11 Best All-Time Low Stocks to Buy According to Analysts - Insider Monkey

Jul 20, 2025
pulisher
Jul 20, 2025

William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Ultragenyx Grants Restricted Stock Units to New Employees, Expands Workforce and Focus on Rare Diseases. - AInvest

Jul 20, 2025
pulisher
Jul 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

Did You Suffer Losses in Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 18, 2025

Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Rare Disease Leader Ultragenyx Expands Team with 45,292 Stock Grants to New Hires - Stock Titan

Jul 18, 2025
pulisher
Jul 18, 2025

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail

Jul 18, 2025
pulisher
Jul 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Reach Out - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Ultragenyx stock hits 52-week low at $26.85 By Investing.com - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 04:31:12 - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Why Ultragenyx Pharmaceutical Inc. stock is on top investor watchlistsDouble Your Capital Alerts - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Sarepta Therapeutics Announces Workforce Reductions as FDA Rejects Ultragenyx Rare Disease Drug Over Manufacturing Concerns - geneonline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Reach Out - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) - Insider Monkey

Jul 17, 2025
pulisher
Jul 17, 2025

Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Connect - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 16, 2025

Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx gets Complete Response Letter for Sanfilippo syndrome gene therapy - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyFree Exclusive Access to Stock Gurus - Newser

Jul 15, 2025

Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):